Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
BIOULTIME : revenue, balance sheet and financial ratios
BIOULTIME is a French company
founded 9 years ago,
specialized in the sector Commerce de gros (commerce interentreprises) de parfumerie et de produits de beauté.
Based in FREJUS (83600),
this company of category ETI
shows in 2025 a net income positive of 2.6 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-08-08
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
Synthèse
Santé financière :
Saine
Aucun signal de fragilité majeur : rentabilité positive et structure financière équilibrée.
In summary, BIOULTIME posts positive profitability over the latest financial year. Its financial structure is solid, with debt well contained relative to its sector.
Revenue and income statement
In 2025, BIOULTIME generates positive net income of 2.6 M€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
Net income (2025)
?
2 560 795 €
Loading income statement...
The detailed income statement is not available for this company (simplified accounts or confidential data).
Assets
Loading data...
Assets balance sheet data not available for this company
Liabilities
Loading data...
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 11%. This ratio is more favorable than the sector median (11.1%). Financial autonomy (= Equity / Total assets x 100) reaches 85%. Compared with its sector, this ratio places the company among the best positioned (sector median: 34.5%).
Debt ratio (2025)
?
10.74%
Financial autonomy (2025)
?
85.11%
Asset age ratio (2025)
?
34.0%
| Indicator |
2019 |
2023 |
2024 |
2025 |
| Debt ratio |
-63.598 |
9.878 |
13.944 |
10.745 |
| Financial autonomy |
-124.392 |
72.54 |
78.856 |
85.105 |
| Repayment capacity |
None |
None |
None |
None |
| Cash flow / Revenue |
None% |
None% |
None% |
None% |
Sector positioning
Q1: 0.79%
Med: 11.05%
Q3: 80.81%
Good
In 2025, the debt ratio of BIOULTIME (10.7%) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Q1: 20.0%
Med: 34.51%
Q3: 67.75%
Excellent
+7 pts over 3 years
In 2025, the financial autonomy of BIOULTIME (85.1%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 16.96. Compared with its sector, this ratio places the company among the best positioned (sector median: 2.6).
Liquidity ratio (2025)
?
16.96
| Indicator |
2019 |
2023 |
2024 |
2025 |
| Liquidity ratio |
0.64338 |
4.88262 |
9.4956 |
16.96423 |
| Interest coverage |
None |
None |
None |
None |
Sector positioning
Q1: 1.4
Med: 2.57
Q3: 4.83
Excellent
+17 pts over 3 years
In 2025, the liquidity ratio of BIOULTIME (16.96) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Positioning of BIOULTIME in its sector
Valuation estimate
Based on 64 transactions of similar company sales
(all years),
the value of BIOULTIME is estimated at
4 614 455 €
(range 2 387 137€ - 30 039 874€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
4 614 455 €
Range: 2 387 137€ - 30 039 874€
NAF 5 all-time
Valuation method used
Net Income Multiple
2 560 795 €
×
1.8x
=
4 614 455 €
Range: 2 387 137€ - 30 039 875€
Only this financial indicator is available for this company.
How is this estimate calculated?
This estimate is based on the analysis of 64 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
- EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
- Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
- Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Top companies in Commerce de gros (commerce interentreprises) de parfumerie et de produits de beauté
Largest companies by revenue in the sector Commerce de gros (commerce interentreprises) de parfumerie et de produits de beauté:
Frequently asked questions about BIOULTIME
What is the revenue of BIOULTIME ?
The revenue of BIOULTIME is not publicly disclosed (confidential accounts filed with INPI).
Is BIOULTIME profitable?
Yes, BIOULTIME generated a net profit of 2.6 M€ in 2025.
Where is the headquarters of BIOULTIME ?
The headquarters of BIOULTIME is located in FREJUS (83600), in the department Var.
Where to find the tax return of BIOULTIME ?
The tax return of BIOULTIME is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does BIOULTIME operate?
BIOULTIME operates in the sector Commerce de gros (commerce interentreprises) de parfumerie et de produits de beauté (NAF code 46.45Z). See the 'Sector positioning' section above to compare the company with its competitors.